Breast Cancer and Pregnancy: Current Concepts in Diagnosis and Treatment

por Litton, Jennifer K., Theriault, Richard L.
Publicado 2010

Characterization of bone only metastasis patients with respect to tumor subtypes

por Parkes, Amanda, Clifton, Katherine, Al-Awadhi, Aydah, Oke, Oluchi, Warneke, Carla L., Litton, Jennifer K., Hortobagyi, Gabriel N.
Publicado 2018

Prospective Evaluation of Universal BRCA Testing for Women With Triple-Negative Breast Cancer

por Emborgo, Trisha S, Saporito, Donika, Muse, Kimberly I, Barrera, Angelica M Gutierrez, Litton, Jennifer K, Lu, Karen H, Arun, Banu K
Publicado 2020

Is the future of personalized therapy in triple-negative breast cancer based on molecular subtype?

por Le Du, Fanny, Eckhardt, Bedrich L., Lim, Bora, Litton, Jennifer K., Moulder, Stacy, Meric-Bernstam, Funda, Gonzalez-Angulo, Ana M., Ueno, Naoto T.
Publicado 2015

Evaluation of BRCAPRO Risk Assessment Model in Patients with Ductal Carcinoma In situ Who Underwent Clinical BRCA Genetic Testing

por Elsayegh, Nisreen, Barrera, Angelica M. Gutierrez, Muse, Kimberly I., Lin, Heather, Kuerer, Henry M., Helm, Monica, Litton, Jennifer K., Arun, Banu K.
Publicado 2016

Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer

por Elsayegh, Nisreen, Webster, Rachel D., Gutierrez Barrera, Angelica M., Lin, Heather, Kuerer, Henry M., Litton, Jennifer K., Bedrosian, Isabelle, Arun, Banu K.
Publicado 2018

Predictors that Influence Election of Contralateral Prophylactic Mastectomy among Women with Ductal Carcinoma in Situ who are BRCA-Negative

por Elsayegh, Nisreen, Profato, Jessica, Barrera, Angelica M. Gutierrez, Lin, Heather, Kuerer, Henry M., Ardic, Can, Litton, Jennifer K., Tripathy, Debasish, Arun, Banu K.
Publicado 2015

Prognostic Factors in Patients with Metastatic Breast Cancer with Bone‐Only Metastases

por Parkes, Amanda, Warneke, Carla L., Clifton, Katherine, Al‐Awadhi, Aydah, Oke, Oluchi, Pestana, Roberto Carmagnani, Alhalabi, Omar, Litton, Jennifer K., Hortobagyi, Gabriel N.
Publicado 2018

Outcomes of children exposed in utero to chemotherapy for breast cancer

por Murthy, Rashmi K, Theriault, Richard L, Barnett, Chad M, Hodge, Silvia, Ramirez, Mildred M, Milbourne, Andrea, Rimes, Sue A, Hortobagyi, Gabriel N, Valero, Vicente, Litton, Jennifer K
Publicado 2014

Use of ACE Inhibitors and Angiotensin Receptor Blockers and Primary Breast Cancer Outcomes

por Chae, Young Kwang, Brown, Erika N., Lei, Xiudong, Melhem-Bertrandt, Amal, Giordano, Sharon H., Litton, Jennifer K., Hortobagyi, Gabriel N., Gonzalez-Angulo, Ana M., Chavez-MacGregor, Mariana
Publicado 2013

Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide GP2 vaccine in breast cancer patients to prevent recurrence

por Mittendorf, Elizabeth A., Ardavanis, Alexandros, Litton, Jennifer K., Shumway, Nathan M., Hale, Diane F., Murray, James L., Perez, Sonia A., Ponniah, Sathibalan, Baxevanis, Constantin N., Papamichail, Michael, Peoples, George E.
Publicado 2016

Local-regional control according to surrogate markers of breast cancer subtypes and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast conserving ther...

por Caudle, Abigail S, Yu, Tse-Kuan, Tucker, Susan L, Bedrosian, Isabelle, Litton, Jennifer K, Gonzalez-Angulo, Ana M, Hoffman, Karen, Meric-Bernstam, Funda, Hunt, Kelly K, Buchholz, Thomas A, Mittendorf, Elizabeth A
Publicado 2012

Rapid Breast Cancer Disease Progression Following Cyclin Dependent Kinase 4 and 6 Inhibitor Discontinuation

por Bashour, Sami I., Doostan, Iman, Keyomarsi, Khandan, Valero, Vicente, Ueno, Naoto T., Brown, Powel H., Litton, Jennifer K., Koenig, Kimberly B., Karuturi, Meghan, Abouharb, Sausan, Tripathy, Debasish, Moulder-Thompson, Stacy L., Ibrahim, Nuhad K.
Publicado 2017

A phase II study of talimogene laherparepvec for patients with inoperable locoregional recurrence of breast cancer

por Kai, Megumi, Marx, Angela N., Liu, Diane D., Shen, Yu, Gao, Hui, Reuben, James M., Whitman, Gary, Krishnamurthy, Savitri, Ross, Merrick I., Litton, Jennifer K., Lim, Bora, Ibrahim, Nuhad, Kogawa, Takahiro, Ueno, Naoto T.
Publicado 2021

Identification of biomarkers of response to preoperative talazoparib monotherapy in treatment naïve gBRCA+ breast cancers

por Liu, Xuan, Ge, Zhongqi, Yang, Fei, Contreras, Alejandro, Lee, Sanghoon, White, Jason B., Lu, Yiling, Labrie, Marilyne, Arun, Banu K., Moulder, Stacy L., Mills, Gordon B., Piwnica-Worms, Helen, Litton, Jennifer K., Chang, Jeffrey T.
Publicado 2022

Association of Body Mass Index Changes during Neoadjuvant Chemotherapy with Pathologic Complete Response and Clinical Outcomes in Patients with Locally Advanced Breast Cancer

por Kogawa, Takahiro, Fouad, Tamer M., Wei, Caimiao, Masuda, Hiroko, Kai, Kazuharu, Fujii, Takeo, El-Zein, Randa, Chavez-MacGregor, Mariana, Litton, Jennifer K., Brewster, Abenaa, Alvarez, Ricardo H., Hortobagyi, Gabriel N., Valero, Vicente, Theriault, Richard, Ueno, Naoto T.
Publicado 2015

Neoadjuvant Talazoparib in Patients With Germline BRCA1/2 Mutation-Positive, Early-Stage Triple-Negative Breast Cancer: Results of a Phase II Study

por Litton, Jennifer K, Beck, J Thaddeus, Jones, Jason M, Andersen, Jay, Blum, Joanne L, Mina, Lida A, Brig, Raymond, Danso, Michael, Yuan, Yuan, Abbattista, Antonello, Noonan, Kay, Niyazov, Alexander, Chakrabarti, Jayeta, Czibere, Akos, Symmans, William F, Telli, Melinda L
Publicado 2023

Talazoparib in Patients with a Germline BRCA‐Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial

por Hurvitz, Sara A., Gonçalves, Anthony, Rugo, Hope S., Lee, Kyung‐Hun, Fehrenbacher, Louis, Mina, Lida A., Diab, Sami, Blum, Joanne L., Chakrabarti, Jayeta, Elmeliegy, Mohamed, DeAnnuntis, Liza, Gauthier, Eric, Czibere, Akos, Tudor, Iulia Cristina, Quek, Ruben G.W., Litton, Jennifer K., Ettl, Johannes
Publicado 2019

Determinants of Response to Talazoparib in Patients with HER2-Negative, Germline BRCA1/2-Mutated Breast Cancer

por Blum, Joanne L., Laird, A. Douglas, Litton, Jennifer K., Rugo, Hope S., Ettl, Johannes, Hurvitz, Sara A., Martin, Miguel, Roché, Henri H., Lee, Kyung-Hun, Goodwin, Annabel, Chen, Ying, Lanzalone, Silvana, Chelliserry, Jijumon, Czibere, Akos, Hopkins, Julia F., Albacker, Lee A., Mina, Lida A.
Publicado 2022

Outcomes in Clinically Relevant Patient Subgroups From the EMBRACA Study: Talazoparib vs Physician’s Choice Standard-of-Care Chemotherapy

por Rugo, Hope S, Ettl, Johannes, Hurvitz, Sara A, Gonçalves, Anthony, Lee, Kyung-Hun, Fehrenbacher, Louis, Mina, Lida A, Diab, Sami, Woodward, Natasha E, Yerushalmi, Rinat, Goodwin, Annabel, Blum, Joanne L, Martin, Miguel, Quek, Ruben G W, Tudor, Iulia Cristina, Bhattacharyya, Helen, Gauthier, Eric, Litton, Jennifer K, Eiermann, Wolfgang
Publicado 2019